Escitalopram-Associated Hypoglycemia and Hypertensive Events
Lexapro (escitalopram) has postmarketing reports of hypoglycemia and hypertensive crisis. [1] Escitalopram-induced blood glucose dysregulation has been reported in patients with diabetes in at least one published case report. [2] Postmarketing reports do not establish incidence, and blood pressure changes are not consistently demonstrated in short-term controlled trials. [1], [3]
Mechanistic Plausibility for Glucose Dysregulation
Escitalopram exposure has been associated with impaired glycemic control in a diabetic patient, with return toward baseline after discontinuation in a reported case. [2] SSRIs have been associated with endocrine/metabolic adverse events in postmarketing surveillance for escitalopram, including hypoglycemia. [1]
Evidence for Hypoglycemia in Diabetes
The FDA label includes hypoglycemia among postmarketing metabolism and nutrition disorders for escitalopram. [1] A published case report described a diabetic older adult with previously controlled glucose measurements who developed increased glycemia shortly after escitalopram initiation and improved after stopping the drug, supporting potential clinically meaningful glucose effects in diabetes. [2]
Evidence for Hypertension in Patients With Cardiovascular Risk
The FDA label includes hypertensive crisis among postmarketing vascular disorders for escitalopram. [1] The FDA label also includes hypotension and orthostatic hypotension, supporting that blood pressure effects can occur in either direction. [1] In an escitalopram randomized controlled trial in major depressive disorder, baseline-to-endpoint changes in systolic and diastolic blood pressure were not significantly different from placebo. [3]
Clinical Implications for Patients With Diabetes or Hypertension
Patients with diabetes may require closer blood glucose monitoring after starting escitalopram or after dose changes because hypoglycemia is listed among postmarketing adverse events for escitalopram. [1] Patients with hypertension may require blood pressure monitoring after starting escitalopram or after dose changes because hypertensive crisis is listed among postmarketing adverse events for escitalopram. [1] Clinically significant symptoms such as symptomatic hypoglycemia or severe blood pressure elevation warrant prompt evaluation and management rather than attributing symptoms solely to underlying diabetes or hypertension. [1]
Common Pitfalls to Avoid
Attributing hypoglycemia solely to diabetes regimen without considering new medications risks delayed recognition of escitalopram-associated hypoglycemia reported in postmarketing experience. [1] Attributing severe blood pressure elevation solely to baseline hypertension without considering new medications risks delayed recognition of escitalopram-associated hypertensive crisis reported in postmarketing experience. [1] Assuming no blood pressure effect because short-term controlled trials did not show significant blood pressure change risks under-recognition of rarer severe events captured through postmarketing reporting. [1], [3]